Abiraterone acetate + dutasteride in treatment of mCRPC

Does adding dutasteride (Avodart) to abiraterone acetate (Zytiga) make any difference in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC)? There is no clear answer to this question from a small, Phase II, pilot study, the results of which have just been published in Clinical Cancer Research. … READ MORE …

Another new biotech company to be focused on treatments for CRPC

Rumor reaches us that another new biotech company, called Fortis Therapeutics, is to be focused (at least initially) on possible new forms of treatment for late stage prostate cancer. … READ MORE …

Living with very advanced forms of prostate cancer

A new article in the journal Supportive Care in Cancer makes the point that informational needs and resources for men dealing with metastatic, castration-resistant prostate cancer continue to be relatively poor — a fact that we would not disagree with. … READ MORE …

Everolimus + bicalutamide in treatment of CRPC?

A small, single-institution, Phase II clinical trial has suggested the possibility that everolimus + bicalutamide may have useful activity in the treatment of some men with castration-resistant prostate cancer. … READ MORE …

Arno starts Phase II testing of onapristone in men with CRPC

According to a media release issued yesterday, Arno Therapeutics has  moved its investigational drug onapristone into the Phase II part of its initial Phase I/II clinical trial in the treatment of very late stage prostate cancer. … READ MORE …

Recommendations of the Prostate Cancer Clinical Trials Working Group 3

Several readers will be interested in looking through a new article that deals with the recommendations from the Prostate Cancer Clinical Trials Working Group 3 on the development of clinical trials of new drugs to treat castration-resistant prostate cancer (CRPC). … READ MORE …

The role of CT scanning in assessment of progression of men with CRPC

A newly published paper in the journal Cancer seems to be implying that every man with castration-resistant prostate cancer who progresses from non-metastatic to metastatic status (based on a bone scan or other indicators) should also be given a CT scan because of risk for soft tissue metastasis. … READ MORE … >